




已阅读5页,还剩30页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Antithombosis in Primary Prevention Where do we stand/where are we going Dr. Carlos Brotons Primary prevention trials with Aspirin: review of the Evidence 1988 British Doctors Trial 1998 Thrombosis Prevention Trial 1998 Hypertension Optimal Treatment (HOT) Study 1999 1989 Physicians Health Study 2001 Primary Prevention Project 2005 Womens Health Study Meta-Analysis of Data from the Six Primary Prevention Trials of Cardiovascular Events Using Aspirin Alfred A. Bartolucci, PhD*, and George Howard, DrPH Am J Cardiol 2006; 98:746 Aspirin in the primary prevention of cardiovascular (CV) events Trial Patient population Age range (years) Aspirin dosage BDT (1988)1 Apparently healthy male physicians (n=5,139) 5078 500mg/day PHS (1989)2 Apparently healthy male physicians (n=22,071) 4084 325mg qod HOT study (1998)3 Men and women with DBP 100115mmHg (n=18,790) 5080 75mg/day TPT (1998)4 Men at high risk of heart disease (n=5,499) 4569 75mg/day PPP (2001)5 Men and women with 1 major CV risk factor (n=4,495) 5080+ 100mg/day WHS (2005)6 Apparently healthy women (n=39,876) 45 100mg qod BDT, British Doctors Trial; HOT, Hypertension Optimal Treatment; PHS, Physicians Health Study; PPP, Primary Prevention Project; qod, every other day; TPT, Thrombosis Prevention Trial; WHS, Womens Health Study. 1. Peto R, et al. BMJ 1988;296:3136; 2. Physicians Health Study. N Engl J Med 1989;321:18258; 3. Hansson L, et al. Lancet 1998;351:175562. 4. The Medical Research Councils General Practice Research Framework. Lancet 1998;351: 23341; 5. de Gaetano G, et al. Lancet 2001;357:8995. 6. Ridker PM, et al. N Engl J Med 2005;352:1293304. Primary findings (total CV events) from the six key trials Study Name Risk Aspirin Control/ Placebo Odds BDT Low 260/3429 127/1710 1.023 0.842 PHS Low 292/11037 390/11034 0.769 0.001 TPT High 208/1268 250/1272 0.741 0.003 HOT Low 243/9399 290/9391 0.824 0.033 PPP Low 46/2226 65/2269 0.546 0.006 WHS Low 539/19934 585/19942 0.982 0.780 TOTAL 1588/47293 1707/45618 0.869 10% over 10 years) once blood pressure has been controlled (as closely as possible to the goal of less than 140/90 mmHg) In lower risk individuals a small absolute vascular benefit by aspirin maybe offset by the slightly greater absolute risk of bleeding complications EJCPR 2007;vol 14(suppl 2):S1-S113 American Heart Association (AHA) Guidelines Benefits of reducing CV risk outweigh these risks in most patients with higher coronary risk Doses of aspirin 75160 mg per day are as effective as higher doses Consider aspirin 75160 mg per day for people at higher risk (especially those with a 10-year CHD risk of 10 percent or greater) Circulation 2002;106:338-391 AHA guidelines for CVD prevention in women (2007 update) Aspirin: high-risk Any vascular disease, end-stage or chronic renal disease, diabetes mellitus, and 10-year Framingham risk 20% Aspirin therapy 75 to 325 mg per day should be used in high-risk women unless contraindicated (Class I, Level A) Circulation 2007;115:1481-1501 Guide to clinical preventive services 2008: recommendations from USPSTF USPSTF strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk for CHD Discussions with patients should address both the potential benefits and harms of aspirin therapy Grade: A Recommendation Guide to clinical preventive services 2008: recommendations from USPSTF Baseline risk for CHD over 5 years: 1% Total mortality: no effect CHD events: 14 avoided Hemorrhagic strokes: 02 caused Major gastrointestinal bleeding events: 24 caused Guide to clinical preventive services 2008: recommendations from USPSTF Baseline risk for CHD over 5 years: 3% Total mortality: no effect CHD events: 412 avoided Hemorrhagic strokes: 02 caused Major gastrointestinal bleeding events: 24 caused Guide to clinical preventive services 2008: recommendations from USPSTF Baseline risk for CHD over 5 years: 5% Total mortality: no effect CHD events: 620 avoided Hemorrhagic strokes: 02 caused Major gastrointestinal bleeding events: 24 caused Who should be treated with aspirin? The decision to use aspirin should be based on a balance of the risks and benefits for each person taking into account their absolute risk for CHD or CVD. Patients with established CVD or very high risk patients should be treated with aspirin unless contraindicated. Before starting treatment with aspirin always consider risks factors for GI bleeding such as age and concomitant use of NSAIDS. An unanswered question In primary prevention is whether the benefits of daily aspirin outweights the harms in specific populations (such as those with moderate risk of CHD) Antithombosis in Primary Prevention Where are we going ? Ongoing trials to assess the benefit:risk profile of low-dose aspirin in the prevention of first CV events The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) Rationale ARRIVE will expand the already existing, strong body of evidence supporting aspirin for primary prevention of CVD events ARRIVE was designed to demonstrate the efficacy and safety of low-dose aspirin in a moderate-risk population CHD risk continuum ARRIVE # of MIs prevented (Per 1,000 patients treated for 10 years) CHD 10-year Risk BENEFIT RISK BENEFIT RISK BENEFIT RISK Overall CHD, Stroke, and CV Death Mean 10-Year Risk (%) CHD (PROCAM and Framingham) STROKE (Framingham) CV Death (SCORE) Total (CVD) High-risk countries 15.8% 9.1% 5.1% 30.0% Risk Estimates by Age and Gender (All Countries) Low-risk countries 8.5% 9.1% 2.75% 20.3% Overall 12.9% 9.1% 4.1% 26.1% Overview of the ARRIVE Trial Sample Size: 12,000 patients (6,000 per group) will be enrolled Duration of Study: approximately 5 years Study Locations: More than 400 trial sites across Germany, Ireland, Italy, Poland, Spain, UK, USA Gender Distribution: 70% male/30% female Intervention: 1:1 daily aspirin (100 mg) or placebo Study design Aspirin daily (100 mg) (n6,000) Placebo 1 tablet daily (n6,000) 12-month visit R=Randomization; *First occurrence of composite outcome of MI, stroke, or cardiovascular death; +Telephone contact Patients (n=12,000) at moderate risk of CVD events R Double-blind treatment
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2023四年级数学上册 3 角的度量第4课时 画角配套说课稿 新人教版
- 2025制造企业承包合同
- 10.2 酸和碱的中和反应(第2课时溶液酸碱度的表示法:pH)说课稿-2025-2026学年九年级化学人教版下册
- Unit 1 What's the matter Section A 2a-2d说课稿 2024-2025学年人教版英语八年级下册
- 第一节 开源硬件系统的微控制器说课稿-2025-2026学年高中信息技术华东师大版2020选择性必修6 开源硬件项目设计-华东师大版2020
- 七年级生物上册 第三单元 第二章 第二节 植株的生长说课稿 (新版)新人教版
- 2025年低空经济区域标准互认对航空教育培训的影响报告
- 考点解析-人教版八年级上册物理声现象《噪声的危害和控制》专项测评试题(含答案解析版)
- 2025年低空经济「未来交通」枢纽建设可行性研究报告
- 2025年粤港澳大湾区低空经济产业投资风险与风险管理报告
- 2025年下半年四川甘孜州考试招聘事业单位人员138人考试参考试题及答案解析
- 2025年10月“江南十校”2026届新高三第一次综合素质检测 化学试卷(含答案详解)
- RCT临床试验课题申报书模板及示范
- 7.水受热遇冷会怎样(教学设计)-四年级上册科学人教鄂教版
- 2025-2030FTTR家庭组网标准演进与市场渗透策略研究
- 屠宰兽医检验考试题及答案
- 2025年成人高考专升本《政治》真题含答案
- 内蒙古信息技术考试题库及答案
- 第四课 建设法治中国说课稿-2025-2026学年初中道德与法治统编版五四学制九年级上册-统编版五四学制2018
- 园林古建筑防雷设计方案
- 老年人体检项目课件
评论
0/150
提交评论